Extended Data Table 2 Demographics of subjects in dose-escalation phase 1 trial of CAN-3110 (Arm A: Cohort 10)

From: Clinical trial links oncolytic immunoactivation to survival in glioblastoma

  1. (related to Sub-heading, Safety of CAN-3110 in rHGG/rGBM patients)
  2. *One subject in cohort 9 (subject 042) was re-treated as part of cohort 10 (subject 054). See explanation in Supplemental Text.
Back to article page